neutral
Recently
Fitch upgrades Biocon Biologics outlook to positive, maintains BB rating
Fitch Ratings upgraded Biocon Biologics’ outlook to positive while maintaining its BB rating, while ICICI Prudential Mutual Fund reopened select international schemes with investment caps.
Fitch Ratings upgraded Biocon Biologics’ outlook to positive while maintaining its long-term issuer default rating at BB, citing improving profitability, scale, and liquidity. The move supported investor sentiment toward the biosimilars business. Separately, ICICI Prudential Mutual Fund has resumed subscriptions in three international schemes, capping investments at ₹2 lakh per PAN to manage inflows while offering measured global equity exposure amid volatile markets conditions today.